StockNews.com Downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to Hold

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Several other analysts have also recently issued reports on the company. Sanford C. Bernstein cut their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Chardan Capital restated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Scotiabank reduced their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research note on Friday, February 14th. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. Finally, William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $304.26.

Alnylam Pharmaceuticals Trading Up 0.1 %

NASDAQ ALNY opened at $253.60 on Friday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market capitalization of $32.83 billion, a price-to-earnings ratio of -116.87 and a beta of 0.39. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The business’s fifty day moving average is $256.25 and its 200-day moving average is $259.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities research analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Jeffrey V. Poulton sold 967 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. This trade represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 in the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Larson Financial Group LLC increased its stake in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares during the period. Park Square Financial Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $28,000. R Squared Ltd purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $33,000. Colonial Trust Co SC purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $35,000. Finally, True Wealth Design LLC boosted its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 153 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.